340 239

Cited 102 times in

A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer

DC FieldValueLanguage
dc.contributor.author노성훈-
dc.contributor.author송시영-
dc.contributor.author이관식-
dc.contributor.author이상인-
dc.contributor.author정현철-
dc.contributor.author조재용-
dc.contributor.author최승호-
dc.date.accessioned2015-07-14T17:12:55Z-
dc.date.available2015-07-14T17:12:55Z-
dc.date.issued2004-
dc.identifier.issn0923-7534-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/112435-
dc.description.abstractBACKGROUND: Capecitabine (Xeloda) is a novel, oral, selectively tumor-activated fluoropyrimidine with proven activity in the treatment of advanced colorectal cancer. This trial was conducted to evaluate the efficacy, safety and feasibility of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer, with a view to replacing 5-fluorouracil (5-FU) in such patients. PATIENTS AND METHODS: Forty-four patients received capecitabine 1250 mg/m2 twice daily (2500 mg/m2/day) for 14 days followed by 7 days of rest, for up to six cycles. RESULTS: Capecitabine produced an objective response rate of 34% (all partial responses) and stable disease in 14 patients (30%). The median time to disease progression (TTP) was 3.2 months [95% confidence interval (CI) 2.7-6.4 months] and median overall survival was 9.5 months (95% CI 6.9-13.2 months). Hand-foot syndrome (HFS), nausea, anorexia, diarrhea and vomiting were the most common adverse events. While HFS was the most frequent grade 3/4 toxicity (National Cancer Institute Common Toxicity Criteria), only 9% of patients experienced grade 3 HFS. Severe myelosuppression was not reported during the study. CONCLUSIONS: Capecitabine monotherapy is active and well tolerated as first-line therapy in patients with advanced/metastatic gastric cancer. Larger comparative trials investigating capecitabine-based combination regimens in patients with advanced gastric cancer are warranted.-
dc.description.statementOfResponsibilityopen-
dc.format.extent1344~1347-
dc.relation.isPartOfANNALS OF ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdministration, Oral-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAnorexia/chemically induced-
dc.subject.MESHAntimetabolites, Antineoplastic/administration & dosage-
dc.subject.MESHAntimetabolites, Antineoplastic/therapeutic use*-
dc.subject.MESHCapecitabine-
dc.subject.MESHDeoxycytidine/administration & dosage-
dc.subject.MESHDeoxycytidine/analogs & derivatives*-
dc.subject.MESHDeoxycytidine/therapeutic use*-
dc.subject.MESHDiarrhea/chemically induced-
dc.subject.MESHFemale-
dc.subject.MESHFluorouracil/analogs & derivatives-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms/secondary-
dc.subject.MESHLung Neoplasms/secondary-
dc.subject.MESHLymphatic Metastasis-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNausea/chemically induced-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHStomach Neoplasms/drug therapy*-
dc.subject.MESHStomach Neoplasms/mortality-
dc.subject.MESHStomach Neoplasms/pathology-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTime Factors-
dc.subject.MESHTreatment Outcome-
dc.titleA phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorY. S. Hong-
dc.contributor.googleauthorS. Y. Song-
dc.contributor.googleauthorJ. Y. Cho-
dc.contributor.googleauthorK. S. Lee-
dc.contributor.googleauthorJ. H. Kang-
dc.contributor.googleauthorJ. Y. Han-
dc.contributor.googleauthorJ. N. Park-
dc.contributor.googleauthorS. H. Noh-
dc.contributor.googleauthorS. H. Choi-
dc.contributor.googleauthorH. C. Chung-
dc.contributor.googleauthorS. I. Lee-
dc.identifier.doi10.1093/annonc/mdh343-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.relation.journalcodeJ00171-
dc.identifier.eissn1569-8041-
dc.identifier.pmid15319239-
dc.contributor.alternativeNameNoh, Sung Hoon-
dc.contributor.alternativeNameSong, Si Young-
dc.contributor.alternativeNameLee, Kwan Sik-
dc.contributor.alternativeNameLee, Sang In-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.alternativeNameCho, Jae Yong-
dc.contributor.alternativeNameChoi, Seung Ho-
dc.rights.accessRightsfree-
dc.citation.volume15-
dc.citation.number9-
dc.citation.startPage1344-
dc.citation.endPage1347-
dc.identifier.bibliographicCitationANNALS OF ONCOLOGY, Vol.15(9) : 1344-1347, 2004-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.